Positrigo

Positrigo is a Swiss medical technology company focused on developing compact and affordable brain Positron Emission Tomography (PET) imaging systems. Founded as a spin-off from ETH Zurich, the company aims to make functional brain imaging widely accessible, enhancing clinical diagnostics, treatment monitoring, and research for brain-related disorders. The flagship product, the NeuroLF system, is an ultra-compact brain PET scanner designed for the early detection and assessment of neurodegenerative diseases, including Alzheimer’s disease, brain tumors, epilepsy, and Parkinson’s disease. NeuroLF is the first device of its kind to receive market clearance in both the US and EU, highlighting its readiness for clinical use. Positrigo's technology allows healthcare providers to perform more scans in limited spaces, addressing a critical need for affordable and accessible brain imaging solutions. The company has successfully raised CHF 7 million in funding to support its production scale-up and commercialization efforts, with additional backing from the European Commission through grants and investments. Positrigo is committed to creating a lasting social impact by making functional brain imaging scalable and accessible worldwide.

• Employees 30
• Founded 2018
• Annual Revenue $3800000
• Total Funding $22433147